Arrowhead Pharmaceuticals (NASDAQ:ARWR – Free Report) had its target price cut by Piper Sandler from $62.00 to $45.00 in a ...

($ARWR) and Sarepta Therapeutics Inc. ($SRPT) climbed on Wednesday despite Wall Street trimming price targets after the ...

On Tuesday, Arrowhead Pharmaceuticals Inc (ARWR) stock saw a modest uptick, ending the day at $21.05 which represents a slight increase of $2.26 or 12.03% from the prior close of $18.79. The stock ...

Arrowhead Pharmaceuticals' stock rallied 17% due to significant pipeline developments and strategic partnerships. Learn more ...

Shares of Arrowhead Pharmaceuticals ($ARWR) surged as much as 22% in pre-market trading on Tuesday after announcing a $825 ...

Strategic Sarepta partnership and FDA filing position Arrowhead for a transformative leap in RNAi therapeutics ...

Morgan Stanley analyst Michael Ulz maintained a Hold rating on Arrowhead Pharmaceuticals (ARWR – Research Report) today and set a price target ...

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) shares are trading higher Tuesday after the company announced a global ...

TD Cowen analyst Brendan Smith has maintained their bullish stance on ARWR stock, giving a Buy rating on November 20.Don't Miss our Black ...

Q4 2024 Earnings Conference Call November 26, 2024 4:30 PM ET. Company Participants. Vince Anzalone - VP, IR Chris Anzalone - Preside ...

Arrowhead Pharmaceuticals is a biotechnology company focused on developing RNA interference (RNAi) therapeutics. Their proprietary platform, Targeted RNAi Molecule (TRiM™), allows them to target and ...

Arrowhead Pharmaceuticals (NASDAQ:ARWR – Get Free Report) is scheduled to be posting its quarterly earnings results after the ...